Skip to main content
SpringerLink
Log in

Immune Mediated Tumor Destruction: Challenges for the 1990’s

  • Chapter
Combination Therapies

Abstract

Numerous experimentally induced tumor models, studied in murine systems, have indicated that successful approaches towards the immune eradication of neoplasms should be a clinical possibility. Central to many of these therapeutic approaches in mice are distinct roles for T lymphocytes, able to mediate antigen specific “major histo-compatibility complex (MHC) -restricted” recognition of tumor cells, as well as natural killer (NK) cells, able to destroy certain tumors in a less specific way, and without requiring the recognition of MHC molecules. Despite the myriad of algorithms enabling effective tumor destruction in vitro or in mice utilizing these immune cell populations, successful application of these principles in patients has been possible only in the past few years. Immune mediated destruction of tumors directly in patients, apparently by activated lymphocytes, has now been reproducibly documented utilizing a number of clinical regimens. Even so, the majority of patients receiving these approaches do not show measurable clinical benefit. Thus, substantial improvement is required to enable practical and effective wide-spread application of these immunologic principles to patients with otherwise refractory cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. M.M. Horowitz, R.P. Gale, P.M. Sondel, J.M. Goldman, J. Kersey, H-J. Kolb, A.A. Rimm, O. Ringden, C. Rozman, B. Speck, R.L. Truitt, F.E. Zwaan, and M.M. Bortin. Graft-vs-leukemia reactions following bone marrow transplantation. Blood 75:555 (1990).

    PubMed  CAS  Google Scholar 

  2. P.M. Sondel, J.A. Hank, J. Molenda, J. Blank, W. Borcherding, W. Longo, M.E. Trigg, R. Hong, and M.J. Bozdech. Relapse of host leukemic lymphoblasts following engraftment by an HLA-mismatched marrow transplant: mechanisms of escape from the “graft versus leukemia” effect. Exper. Hematol. 13:782 (1985).

    CAS  Google Scholar 

  3. P.M. Sondel, J.A. Hank, P.C. Kohler, B.P. Chen, D.Z. Minkoff, and J. Molenda. Destruction of autologous human lymphocytes by interleukin-2-activated cytotoxic cells. J. Immunol. 137:502 (1986).

    PubMed  CAS  Google Scholar 

  4. P. Fisch, G. Weil-Hillman, M. Uppenkamp, J.A. Hank, B.P. Chen, J.A. Sosman, A. Bridges, O.R. Colamonici, and P.M. Sondel. Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2 activated cytotoxic T-cells from a patient with acute T-cell leukemia. Blood 74:343 (1989).

    PubMed  CAS  Google Scholar 

  5. K. Itoh, C. Platsoucas, and C. Balch. Autologous tumor specific cytoxic T lymphocytes in the infiltrate of human metastatic melanoma. J. Exper. Med. 168:1419 (1988).

    Article  CAS  Google Scholar 

  6. M.R. Albertini, J.A. Nicklas, B.F. Chastenay, T.C. Hunter, R.J. Albertini, J.A. Hank, and P.M. Sondel. Analysis of T-cell receptor gamma and beta genes from peripheral blood, regional lymph nodes and tumor infiltrating lymphocyte clones from melanoma patients. Cancer Immunol. Immunother. 32:325 (1991).

    Article  PubMed  CAS  Google Scholar 

  7. J.A. Sosman, K.R. Oettel, J.A. Hank, P. Fisch, and P.M. Sondel. Specific recognition of human leukemic cells by allogeneic T cell lines. Transplantation 48:486 (1989).

    Article  PubMed  CAS  Google Scholar 

  8. J.A. Sosman, K. Oettel, S.D. Smith, J.A. Hank, P. Fisch, and P.M. Sondel. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted unique determinants on leukemic cells which are cross-reactive with determinants present on unrelated non-leukemic cells. Blood 75:2005 (1990).

    PubMed  CAS  Google Scholar 

  9. J.A. Sosman and P.M. Sondel. The Graft Versus Leukemia Effect: Possible mechanisms and clinical significance to the Biologic Therapy of Leukemia. Bone Marrow Transplantation, In press, 1991.

    Google Scholar 

  10. B.P. Chen, M. Malkovsky, J.A. Hank, J.A. Molenda, and P.M. Sondel. Nonrestricted cytotoxicity mediated by interleukin-2 expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb. Cellular Immunol. 110:282 (1987).

    Article  CAS  Google Scholar 

  11. B.P. Chen, J.A. Hank, E.E. Kraus, and P.M. Sondel. Selective lysis of target cells by interleukin-2 expanded peripheral blood mononuclear leukocyte clones. Cellular Immunol. 118:458 (1989).

    Article  CAS  Google Scholar 

  12. P. Fisch, M. Malkovsky, E. Braakman, R.L.H. Bolhuis, A. Prieve, J.A. Sosman, V.A. Lam, and P.M. Sondel PM. Gamma/delta T-cell clones and natural killer-cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J. Exp. Med. 171:1567 (1990).

    Article  PubMed  CAS  Google Scholar 

  13. E. Sturm, E. Braakman, P. Fisch, R.J. Vreugdenhil, P.M. Sondel, and R.L.H. Bolhuis. MCH unrestricted cytotoxic activity of cloned human TCR lymphocytes: Specific lysis of Daudi cells correlates with the usage of a gamma 9-delta 2 TCR gene-rearrangement. J. Immunol. 145:3202 (1990).

    PubMed  CAS  Google Scholar 

  14. P. Fisch, M. Malkovsky, S. Kovats, E. Sturm, E. Braakman, B.S. Klein, S.D. Voss, L.W. Morrissey, R. DeMars, W.J. Welch, R.L.H. Bolhuis, and P.M. Sondel. Recognition by Human V-gamma 9/V-delta 2 T cells of a GroEL homolog on Daudi Burkitt’s lymphoma cells. Science 250:1269 (1990).

    Article  PubMed  CAS  Google Scholar 

  15. P.M. Sondel, P.C. Kohler, J.A. Hank, K.H. Moore, N. Rosenthal, J. Sosman, R. Bechhofer, and B. Storer. Clinical and immunologic effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res. 48:2561 (1988).

    PubMed  CAS  Google Scholar 

  16. J.A. Hank, P.C. Kohler, G.W. Hillman, N. Rosenthal, K.H. Moore, B. Storer, D. Minkoff, J. Bradshaw, R. Bechhofer, and P.M. Sondel. In vivo induction of the lymphokine-activated killer phenomenon: Interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res. 48:1965 (1988).

    PubMed  CAS  Google Scholar 

  17. J.A. Hank, G.W. Hillman, J.E. Surfus, J.A. Sosman, and P.M. Sondel. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol. Immunother. 31:53 (1990).

    Article  PubMed  CAS  Google Scholar 

  18. J.A. Sosman, P.C. Kohler, J.A. Hank, K.H. Moore, R. Bechhofer, B. Storer, and P.M. Sondel. Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J. Natl. Cancer Inst. 80:60 (1988).

    Article  PubMed  CAS  Google Scholar 

  19. J.A. Sosman, P.C. Kohler, J.A. Hank, K.H. Moore, R. Bechhofer, B. Storer, and P.M. Sondel. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule and indomethacin. J. Natl. Cancer Inst. 80:1451 (1988).

    Article  PubMed  CAS  Google Scholar 

  20. M.R. Albertini, J.A. Sosman, J.A. Hank, K.H. Moore, A. Borchert, K. Schell, P.C. Kohler, R. Bechhofer, B. Storer, and P.M. Sondel. The influence of autologous lymphokine-activated killer-cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer 66:2457 (1990).

    Article  PubMed  CAS  Google Scholar 

  21. S.A. Rosenberg, B. Packard, P. Aebersold, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl. J. Med. 319:1676 (1988).

    Article  PubMed  CAS  Google Scholar 

  22. P.M. Sondel, J.A. Sosman, J.A. Hank, P.C. Kohler, and B. Storer. Tumor infiltrating lymphocytes and interleukin-2 in melanomas. New Engl. J. Med. (letter) 320:1418 (1989).

    CAS  Google Scholar 

  23. J.A. Hank, J.A. Sosman, P.C. Kohler, R. Bechhofer, B. Storer, and P.M. Sondel. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with IL-2. J. Biol. Resp. Mod. 9:5 (1990).

    CAS  Google Scholar 

  24. A.C. Ochoa, G. Gromo, B.J. Alter, P.M. Sondel, and F.H. Bach. Long-term growth of lymphokine activated killer (LAK) cells: Role of anti-CD3, Beta-IL 1, interferon-Gamma and -Beta. J. Immunol. 138:2728 (1987).

    PubMed  CAS  Google Scholar 

  25. J.D.I. Ellenhorn, R. Hirsch, H. Schreiber, and J.A. Bluestone. In vivo administration of anti CD-3 prevents malignant progressor tumor growth. Science 242:569 (1988).

    Article  PubMed  CAS  Google Scholar 

  26. G. Weil-Hillman, K. Schell, D.M. Segal, J.A. Hank, J.A. Sosman, and P.M. Sondel. Activation of human T cells obtained pre and post IL-2 therapy by anti-CD3 monoclonal antibody plus IL-2: anti CD3 treatment prior to in vivo IL-2 therapy induces greater T cell activation. J. Immunother., in press, 1991.

    Google Scholar 

  27. J.A. Hank, R.R. Robinson, J. Surfus, B.M. Mueller, R.A. Reisfeld, N.K. Cheung, and P.M. Sondel. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res. 50:5234 (1990).

    PubMed  CAS  Google Scholar 

  28. W.A. Bleyer. The impact of childhood cancer on the United States and the world. CA-A Cancer J. for Clinicians. 40:355 (1990).

    Article  CAS  Google Scholar 

  29. P.M. Sondel, J.A. Hank, G. Weil-Hillman, P. Fisch, M. Albertini, S. Voss, and J.A. Sosman. The immunotherapy of cancer: Prospects for more specific antitumor efficacy. in: “The Cellular Immunology and Immunotherapy of Cancer,” O. Finn and M. Lotze, eds., Alan R. Liss Inc., New York, p. 413 (1990).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pediatrics, Human Oncology and Genetics, The University of Wisconsin, Madison, Wisconsin, USA

    Paul M. Sondel

Authors
  1. Paul M. Sondel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The George Washington University School of Medicine, Washington, D.C., USA

    Allan L. Goldstein

  2. University of Rome “Tor Vergata”, Rome, Italy

    Enrico Garaci

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sondel, P.M. (1992). Immune Mediated Tumor Destruction: Challenges for the 1990’s. In: Goldstein, A.L., Garaci, E. (eds) Combination Therapies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3340-5_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3340-5_23

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6472-6

  • Online ISBN: 978-1-4615-3340-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation